A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer

NCT00564928 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Prostatic Neoplasms
Cancer of the Prostate

Interventions

DRUG: IPI-504

Sponsor

Infinity Pharmaceuticals, Inc.